CNS - Plus Therapeutics shares up 7% after reporting ReSPECT-LM phase 1 trial data
2023-08-11 09:06:20 ET
- Plus Therapeutics, Inc. ( NASDAQ: PSTV ) up 7% on Friday after it reported positive data from the ReSPECT-LM clinical study evaluating the company’s lead radiotherapeutic, rhenium (( 186 Re)) obisbemeda, for treatment of leptomeningeal metastases (LM).
- The data was reported at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference.
- Rhenium obisbemeda is a novel injectable radiotherapy specifically formulated to directly deliver targeted high-dose radiation in CNS tumors in a safe, effective, and convenient administration.
- Source: Press Release
For further details see:
Plus Therapeutics shares up 7% after reporting ReSPECT-LM phase 1 trial data